遺伝性血管性浮腫治療薬の世界市場- 産業規模、動向、機会、予測、2018年～2028年：薬剤クラス別、流通経路別、用途別、地域別、競合

遺伝性血管性浮腫治療薬の世界市場は、2022年に31億2,000万米ドルと評価され、2028年までのCAGRは7.23%で、予測期間中に力強い成長が予測されています。

世界の遺伝性血管性浮腫（HAE）治療薬市場は、医薬品・バイオテクノロジー産業の中でもダイナミックで急速に発展している分野です。遺伝性血管性浮腫は、皮膚、胃腸管、上気道など、身体の様々な部位における腫脹の反復的かつ予測不能なエピソードを特徴とする稀な遺伝性疾患です。これらのエピソードは、気道が侵されると生命を脅かす可能性があり、HAEと共に生きる患者にとって、効果的な治療薬が非常に必要となっています。

近年、HAE治療薬市場は、研究開発の進歩、認知度の向上、診断技術の改善により、大きな成長を遂げています。特に、C1エステラーゼ阻害剤（C1-INH）と呼ばれるタンパク質の活性を特異的に阻害する標的モノクローナル抗体の出現が挙げられます。これらの治療法は、発作の予防と管理により効果的で便利な選択肢を提供することで、HAE患者の治療状況を一変させました。

さらに、診断の改善と疾患に対するより深い理解により、患者数が拡大していることも、この市場の利益となっています。認知度が高まり、より多くの患者が正しく診断されるようになるにつれ、HAE治療薬に対する需要は増加すると予想されます。しかし、このような進歩にもかかわらず、高い治療費、アクセスの問題、長期的な安全性と有効性に関するさらなる研究の必要性などの課題が依然として存在することに留意する必要があります。

市場促進要因

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 遺伝性血管性浮腫治療薬の世界市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別（C1エステラーゼ阻害薬、選択的ブラジキニンB2受容体拮抗薬、カリクレイン阻害薬、その他薬剤クラス別）
  • 流通チャネル別（病院薬局、小売薬局、その他の流通チャネル）
  • 用途別（予防、オンデマンド）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 薬剤クラス別
  • 流通チャネル別
  • 用途別
  • 地域別

第5章 アジア太平洋地域の遺伝性血管性浮腫治療薬市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • 流通チャネル別
  • 用途別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の遺伝性血管性浮腫治療薬市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • 流通チャネル別
  • 用途別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の遺伝性血管性浮腫治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • 流通チャネル別
  • 用途別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の遺伝性血管性浮腫治療薬市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • 流通チャネル別
  • 用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの遺伝性血管性浮腫治療薬市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • 流通チャネル別
  • 用途別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 遺伝性血管性浮腫治療薬の世界市場SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Shire plc
• Sanofi SA
• Pharming Healthcare Inc.
• Attune Pharmaceuticals
• Adverum Biotechnologies
• Arrowhead Pharmaceuticals
• Ionis Pharmaceuticals
• BioCryst Pharmaceuticals Inc.
• CSL Behring.
• CENTOGENE N.V.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Hereditary Angioedema Therapeutics Market has valued at USD 3.12 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 7.23% through 2028. The Global Hereditary Angioedema (HAE) Therapeutics Market is a dynamic and rapidly evolving sector within the pharmaceutical and biotechnology industries. Hereditary Angioedema is a rare genetic disorder characterized by recurrent and unpredictable episodes of swelling in various parts of the body, including the skin, gastrointestinal tract, and upper airways. These episodes can be life-threatening if they involve the airway, making effective therapeutics a critical necessity for patients living with HAE.

In recent years, the HAE therapeutics market has witnessed significant growth, driven by advancements in research and development, increased awareness, and improved diagnostic techniques. One of the key drivers of market growth is the development of novel therapies, particularly the emergence of targeted monoclonal antibodies that specifically inhibit the activity of a protein called C1 esterase inhibitor (C1-INH). These therapies have revolutionized the treatment landscape for HAE patients by providing more effective and convenient options for preventing and managing attacks.

Furthermore, the market is also benefiting from the expanding patient pool due to improved diagnosis and a better understanding of the disease. As awareness grows and more patients are correctly diagnosed, the demand for HAE therapeutics is expected to rise. However, it is essential to note that despite these advancements, challenges such as high treatment costs, accessibility issues, and the need for further research into long-term safety and efficacy still exist.

Key Market Drivers

Advancements in Research and Development (R&D)

Advancements in Research and Development (R&D) have been pivotal in boosting the Global Hereditary Angioedema (HAE) Therapeutics Market. Hereditary Angioedema is a rare genetic disorder characterized by debilitating and unpredictable swelling episodes that can be life-threatening. In recent years, the relentless pursuit of scientific knowledge and innovative therapies has transformed the landscape of HAE treatment.

One of the most significant drivers of market growth has been the breakthrough discoveries in understanding the underlying mechanisms of HAE. Researchers have delved deep into the genetic and biochemical aspects of the disease, leading to a more precise understanding of how it develops and progresses. This increased knowledge has paved the way for the development of targeted therapies that are specifically designed to address the root causes of HAE.

Monoclonal antibodies, in particular, have emerged as a revolutionary approach in HAE therapeutics. These monoclonal antibodies, such as Lanadelumab and Ecallantide, have been engineered to specifically inhibit the activity of proteins like C1 esterase inhibitor (C1-INH), which play a critical role in HAE attacks. This precision in drug design has proven highly effective in preventing and managing HAE episodes, providing patients with newfound hope and relief from the burden of their condition.

Furthermore, the collaboration between pharmaceutical companies, academic institutions, and research organizations has facilitated the rapid translation of scientific discoveries into tangible treatments. This synergy has accelerated the development and approval of innovative therapies, ensuring that they reach the patients who need them in a timely manner.

The advancements in R&D have not only led to the discovery of novel treatments but have also expanded the understanding of HAE subtypes and disease variations. This knowledge has paved the way for personalized medicine approaches, tailoring treatments to suit individual patients' needs and genetic profiles.

Emergence of Monoclonal Antibodies

The emergence of monoclonal antibodies has played a transformative role in boosting the Global Hereditary Angioedema (HAE) Therapeutics Market. Monoclonal antibodies are a class of biologic drugs engineered to target specific proteins or molecules with remarkable precision, and they have proven to be a game-changer in the treatment of HAE.

Hereditary Angioedema is a rare genetic disorder characterized by recurrent and unpredictable swelling episodes, often involving the skin, gastrointestinal tract, or airways. These attacks can be severe and life-threatening, making effective treatment essential for patients' well-being.

Monoclonal antibodies have offered a groundbreaking approach to HAE therapeutics by targeting key factors involved in the disease's pathogenesis. For instance, drugs like Lanadelumab and Ecallantide have been developed to specifically inhibit the activity of C1 esterase inhibitor (C1-INH), a protein central to HAE attacks. By precisely targeting the root causes of HAE, these monoclonal antibodies have proven highly effective in preventing and managing episodes, reducing their frequency and severity.

One of the remarkable advantages of monoclonal antibodies is their convenience and reliability. Unlike traditional treatments that require frequent injections or infusions, monoclonal antibodies are administered less frequently, often once every two weeks or even less, depending on the specific medication. This not only improves the patient's quality of life by reducing treatment burden but also enhances treatment compliance, which is crucial for managing a chronic condition like HAE effectively.

Moreover, the introduction of monoclonal antibodies has reshaped the overall treatment landscape for HAE. These medications have become a preferred choice for healthcare providers and patients alike due to their proven efficacy and safety profiles. As a result, they have gained significant attention and have been incorporated into updated treatment guidelines.

The emergence of monoclonal antibodies in HAE therapeutics has not only benefited patients but has also encouraged pharmaceutical companies to invest in research and development in this area. This has led to a more competitive market, with a variety of treatment options, fostering innovation and further advancement in the field.

Increased Disease Awareness

Increased disease awareness has played a significant role in boosting the Global Hereditary Angioedema (HAE) Therapeutics Market. Hereditary Angioedema is a rare genetic disorder characterized by recurrent and often debilitating swelling episodes that can affect various parts of the body, including the skin, gastrointestinal tract, and airways. Historically, HAE has been underdiagnosed or misdiagnosed due to its rarity and the lack of awareness among healthcare professionals. However, in recent years, there has been a noticeable shift in the perception and recognition of this condition.

One of the key drivers behind the growing HAE therapeutics market is the heightened awareness of HAE among healthcare providers. Medical professionals, including allergists, immunologists, and emergency room physicians, are now better equipped to identify and diagnose HAE accurately. This improvement in diagnostic accuracy has led to more patients receiving the appropriate medical attention and treatment, thus expanding the patient pool in need of HAE therapeutics.

In addition to healthcare professionals, patient advocacy groups and organizations have played a crucial role in increasing awareness about Hereditary Angioedema. Groups such as the HAE Association and HAEi (Hereditary Angioedema International) have been actively involved in raising awareness, providing support to patients and their families, and advocating for better access to treatment options. Their efforts have not only empowered patients to seek proper medical care but have also influenced policy changes and increased funding for HAE research and development.

The rise of the internet and social media platforms has further contributed to disease awareness. Patients and their families are now able to connect with one another, share their experiences, and access valuable information about HAE. This online community has become a powerful force in educating the public and dispelling myths surrounding the condition..

Key Market Challenges

High Treatment Costs

The High treatment costs have emerged as a significant obstacle hindering the growth and accessibility of the Global Hereditary Angioedema (HAE) Therapeutics Market. HAE is a rare genetic disorder characterized by recurrent and potentially life-threatening swelling episodes. While advancements in therapeutics have improved the quality of life for HAE patients, the exorbitant cost of these treatments poses a considerable challenge. The prohibitively high cost of treatment makes these life-saving therapies inaccessible to a substantial portion of HAE patients, especially those without comprehensive health insurance coverage. This leads to disparities in access to care, with only a fraction of those in need benefiting from the latest advancements in HAE therapeutics.

For individuals who manage to access HAE therapies, the financial strain can be overwhelming. Copayments, deductibles, and out-of-pocket expenses can quickly accumulate, potentially forcing patients to make difficult choices between their healthcare needs and other essential expenses.

Access to HAE treatments is even more challenging in regions with limited healthcare resources and lower income levels. This exacerbates global healthcare disparities, where patients in wealthier nations have greater access to cutting-edge treatments, while those in less affluent regions struggle to secure even basic care.

High treatment costs can impact patients' adherence to prescribed regimens. Some individuals may skip doses or discontinue treatment due to financial constraints, jeopardizing their health and increasing the risk of severe HAE attacks.

The high cost of HAE therapies places a strain on healthcare systems and insurance providers. As demand for these treatments increases with growing awareness and diagnoses, managing the financial aspects of providing these therapies becomes an ongoing challenge for healthcare stakeholders.

Complex Diagnosis and Misdiagnosis

complex diagnosis and misdiagnosis pose significant challenges to the Global Hereditary Angioedema (HAE) Therapeutics Market. HAE is a rare genetic disorder characterized by recurrent and unpredictable swelling episodes, which can affect various body parts, including the skin, gastrointestinal tract, and airways. Despite advancements in our understanding of the disease, diagnosing HAE remains a complex and often elusive task.

As HAE affects only a small percentage of the population, many healthcare providers may lack experience in recognizing its symptoms. Furthermore, the symptoms of HAE can mimic those of other more common conditions, such as allergies or gastrointestinal disorders, leading to misdiagnosis or delayed diagnosis. This delay can have serious consequences for patients, as they may receive inappropriate treatments that do not address the root causes of their symptoms.

Misdiagnosis or delayed diagnosis can result in patients not receiving appropriate HAE-specific therapies promptly. This delay can lead to increased suffering, more severe attacks, and a higher risk of life-threatening complications.

Misdiagnosed patients may undergo unnecessary medical procedures, tests, or treatments, consuming healthcare resources that could be better utilized elsewhere. This inefficiency can strain healthcare systems and contribute to rising healthcare costs.

The accurate identification of HAE patients is crucial for conducting effective clinical trials of new therapies. Misdiagnosis or inclusion of patients with different conditions can skew trial results, making it difficult to evaluate the safety and efficacy of potential treatments.

Complex diagnosis and misdiagnosis underscore the importance of patient advocacy and education. Patient advocacy groups and organizations play a crucial role in raising awareness, providing resources, and supporting individuals in their journey to accurate diagnosis and appropriate treatment.

Key Market Trends

Personalized Medicine Approaches

Personalized medicine approaches are playing a pivotal role in boosting the Global Hereditary Angioedema (HAE) Therapeutics Market. HAE, a rare genetic disorder characterized by recurrent and potentially life-threatening swelling episodes, has seen remarkable advancements in treatment, thanks to the trend toward personalized medicine. This approach tailors treatments to individual patients based on their unique genetic profiles and disease characteristics.

In HAE, personalized medicine begins with genetic testing to identify specific mutations associated with the condition. As there are multiple subtypes of HAE, each with distinct genetic mutations, this step is crucial for accurate diagnosis. Genetic testing enables healthcare providers to determine the subtype of HAE a patient has, allowing for a more precise and targeted treatment plan.

Once a specific subtype is identified, treatment strategies can be customized to address the underlying genetic and biochemical factors contributing to HAE. This tailored approach minimizes the risk of adverse effects and maximizes treatment effectiveness. For example, patients with a deficiency in C1 esterase inhibitor (C1-INH) may benefit from therapies that replace this missing protein, while those with excessive bradykinin production may require treatments that inhibit its effects.

Personalized medicine also extends to the ongoing management of HAE. Individualized treatment plans can be adjusted based on a patient's response to therapy, optimizing their long-term care. This approach reduces the trial-and-error aspect of treatment and enhances patient outcomes.

Advancements in Diagnostic Techniques

Advancements in diagnostic techniques are significantly boosting the Global Hereditary Angioedema (HAE) Therapeutics Market. HAE is a rare genetic disorder characterized by recurrent and unpredictable swelling episodes, and the accuracy and speed of diagnosis have long been a challenge. However, recent developments in diagnostic techniques have revolutionized the way HAE is identified and managed.

Genetic testing is one of the most crucial advancements in HAE diagnosis. By analyzing a patient's DNA, healthcare providers can identify specific genetic mutations associated with HAE, allowing for precise subtype classification. This genetic information is invaluable in tailoring treatment plans to address the underlying genetic and biochemical factors contributing to the disease. Genetic testing has significantly reduced the risk of misdiagnosis or delayed diagnosis, ensuring that patients receive the most appropriate care from the outset.

Furthermore, advancements in biomarker identification have enhanced the accuracy and efficiency of HAE diagnosis. Biomarkers are specific molecules or proteins in the body that can indicate the presence and severity of the disease. Researchers have identified certain biomarkers associated with HAE, such as elevated levels of bradykinin. These biomarkers can be detected through blood tests, providing an additional diagnostic tool that helps confirm HAE diagnoses and assess disease activity.

The adoption of these advanced diagnostic techniques has several implications for the HAE therapeutics market. First, it reduces the time to diagnosis, allowing patients to start treatment sooner, which is crucial for managing the disease effectively. Second, it minimizes the risk of misdiagnosis or incorrect subtype classification, preventing patients from receiving inappropriate treatments. Third, it fosters confidence among healthcare providers, ensuring they can make informed decisions about the most suitable therapies for their patients.

Segmental Insights

Drug Class Insights

Based on the Drug Class, C1 Esterase Inhibitor (C1-INH) emerged as the dominant segment in the global market for Global Hereditary Angioedema Therapeutics Market in 2022 .C1-INH replacement therapy has a long history of success in managing HAE attacks. It directly addresses the underlying cause of HAE, which is the deficiency or dysfunction of C1-INH, a protein involved in regulating the bradykinin pathway. By restoring adequate levels of C1-INH, these therapies effectively prevent and treat HAE attacks.

C1-INH therapies offer various administration options, including intravenous (IV) infusion and subcutaneous (SC) injection. This flexibility allows healthcare providers to tailor treatment plans to individual patient preferences and needs. For instance, some patients may prefer the convenience of self-administered SC injections, while others may opt for IV infusion in a clinical setting.

Distribution Channel Insights

Based on the Distribution Channel, the Retail Pharmacy segment emerged as the dominant player in the global market for Global Hereditary Angioedema Therapeutics Market in 2022. Retail pharmacies are widely accessible to the general population. They are found in local communities and neighborhoods, making it convenient for patients to access their prescribed medications without having to travel long distances or visit specialized medical facilities.

Retail pharmacies offer a convenient and familiar environment for patients to pick up their HAE medications. Patients can combine their regular visits to the pharmacy with other shopping or errands, saving them time and effort.

Regional Insights

North America emerged as the dominant player in the global Hereditary Angioedema Therapeutics Market in 2022, holding the largest market share. North America has a relatively higher prevalence of HAE compared to other regions. This increased disease burden contributes to a larger patient population seeking treatment, which, in turn, drives the demand for HAE therapeutics.

The region boasts a well-developed and advanced healthcare infrastructure, including a network of specialized treatment centers, hospitals, and clinics. This infrastructure facilitates the diagnosis, treatment, and management of HAE, making it easier for patients to access care and therapies.

Key Market Players

• Shire plc

• Sanofi SA

• Pharming Healthcare Inc.

• Attune Pharmaceuticals

• Adverum Biotechnologies

• Arrowhead Pharmaceuticals

• Ionis Pharmaceuticals

• BioCryst Pharmaceuticals Inc.

• CSL Behring.

• CENTOGENE N.V

Report Scope:

In this report, the Global Hereditary Angioedema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Hereditary Angioedema Therapeutics Market, By Drug Class:

• C1 Esterase Inhibitor
• Selective Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Other Drug Classes

Global Hereditary Angioedema Therapeutics Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels

Global Hereditary Angioedema Therapeutics Market, By Application:

• Prophylaxis
• On-demand

Global Hereditary Angioedema Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Hereditary Angioedema Therapeutics Market.

Available Customizations:

• Global Hereditary Angioedema Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Hereditary Angioedema Therapeutics Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes)
  • 4.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
  • 4.2.3. By Application (Prophylaxis, On-demand)
  • 4.2.4. By Region
  • 4.2.5. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Drug Class
  • 4.3.2. By Distribution Channel
  • 4.3.3. By Application
  • 4.3.4. By Region

5. Asia Pacific Hereditary Angioedema Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class
  • 5.2.2. By Distribution Channel
  • 5.2.3. By Application
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Hereditary Angioedema Therapeutics Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Drug Class
      • 5.3.1.2.2. By Distribution Channel
      • 5.3.1.2.3. By Application
  • 5.3.2. India Hereditary Angioedema Therapeutics Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Drug Class
      • 5.3.2.2.2. By Distribution Channel
      • 5.3.2.2.3. By Application
  • 5.3.3. Australia Hereditary Angioedema Therapeutics Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Drug Class
      • 5.3.3.2.2. By Distribution Channel
      • 5.3.3.2.3. By Application
  • 5.3.4. Japan Hereditary Angioedema Therapeutics Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Drug Class
      • 5.3.4.2.2. By Distribution Channel
      • 5.3.4.2.3. By Application
  • 5.3.5. South Korea Hereditary Angioedema Therapeutics Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Drug Class
      • 5.3.5.2.2. By Distribution Channel
      • 5.3.5.2.3. By Application

6. Europe Hereditary Angioedema Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Hereditary Angioedema Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
      • 6.3.1.2.3. By Application
  • 6.3.2. Germany Hereditary Angioedema Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
      • 6.3.2.2.3. By Application
  • 6.3.3. Spain Hereditary Angioedema Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel
      • 6.3.3.2.3. By Application
  • 6.3.4. Italy Hereditary Angioedema Therapeutics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Class
      • 6.3.4.2.2. By Distribution Channel
      • 6.3.4.2.3. By Application
  • 6.3.5. United Kingdom Hereditary Angioedema Therapeutics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Class
      • 6.3.5.2.2. By Distribution Channel
      • 6.3.5.2.3. By Application

7. North America Hereditary Angioedema Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Hereditary Angioedema Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
      • 7.3.1.2.3. By Application
  • 7.3.2. Mexico Hereditary Angioedema Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
      • 7.3.2.2.3. By Application
  • 7.3.3. Canada Hereditary Angioedema Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel
      • 7.3.3.2.3. By Application

8. South America Hereditary Angioedema Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Hereditary Angioedema Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
      • 8.3.1.2.3. By Application
  • 8.3.2. Argentina Hereditary Angioedema Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
      • 8.3.2.2.3. By Application
  • 8.3.3. Colombia Hereditary Angioedema Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel
      • 8.3.3.2.3. By Application

9. Middle East and Africa Hereditary Angioedema Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Hereditary Angioedema Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
      • 9.3.1.2.3. By Application
  • 9.3.2. Saudi Arabia Hereditary Angioedema Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
      • 9.3.2.2.3. By Application
  • 9.3.3. UAE Hereditary Angioedema Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel
      • 9.3.3.2.3. By Application
  • 9.3.4. Egypt Hereditary Angioedema Therapeutics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Drug Class
      • 9.3.4.2.2. By Distribution Channel
      • 9.3.4.2.3. By Application

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Hereditary Angioedema Therapeutics Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Shire plc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Sanofi SA
• 14.3. Pharming Healthcare Inc.
• 14.4. Attune Pharmaceuticals
• 14.5. Adverum Biotechnologies
• 14.6. Arrowhead Pharmaceuticals
• 14.7. Ionis Pharmaceuticals
• 14.8. BioCryst Pharmaceuticals Inc.
• 14.9. CSL Behring.
• 14.10. CENTOGENE N.V.

15. Strategic Recommendations

16. About Us & Disclaimer